The global neuroprotection market was valued at approximately US$
47,000.0 Mn in 2016 is projected to register a growth rate of 8.2%
from 2017 to 2025, according to a new report published by
Transparency Market Research (TMR) titled “Neuroprotection Market –
Global Industry Analysis, Size, Share, Growth, Trends, and Forecast,
2017–2025”. The report suggests that increasing incidence and
prevalence rates of neurological disorders such as Alzheimer’s,
Parkinson’s, Macular Sclerosis ,and other neurological conditions
causing neural damage is expected to assist the growth of
neuroprotection market in the coming years (2017 to 2025). As major
drug manufacturers are growing their product portfolios by increasing
product development in developed markets such a North America and
Europe region along with increasing strategic collaboration with
regional players in developing economies. The North America, Europe,
and Asia Pacific regions are likely to account for major share in the
global neurprotection market. Increasing drug trials, growing
awareness for neurological disorders, and increasing healthcare
infrastructure in emerging markets such as India is likely to drive
the growth of neuroprotection market in Asia Pacific, the market is
anticipated to exhibit a CAGR of 9.9% from 2017 to 2025.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=40553
Neuroprotection is the property of drugs which are used in prevention
of neuronal degradation by deterring one or more than one
pathophysiological phases in the progressions which follow brain
ischemia due to occlusion of a cerebral artery or neurodegenerative
processes. These neuroprotective agents play an important role in the
management of neurodegenerative diseases as well as in central
nervous system trauma, cerebral ischemia, and other conditions.
Rapid increase in pharmaceutical sector and increasing patient
population has led to an increased demand for neuroprotective drugs
as they prove to be highly efficient in treatment of
neurodegenerative diseases such as Alzheimer’s, Parkinson’s,
Macular Sclerosis ,and other diseases where neural damage takes
place. These drivers along with increasing incidences of traumatic
brain injury are expected to drive the Neuroprotection market during
the forecast period.
For instance, TBI is a contributing factor to a third (30%) of all
injury-related deaths in the U.S.
The global Neuroprotection market has been segmented into product,
application, and region. On the basis of product the Neuroprotection
market has been further segmented as; Free Radical Trapping Agents
(Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents),
Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors
(NTFs), Metal Ion Chelators, Stimulants, and Others. During the
forecast period 2017-2025 the free radical trapping agents
(antioxidants) is expected to expand at a higher rate of CAGR to
reach a market value of approximately US$ 18,000.0 Mn by 2025.The
free radical trapping agent product held major share in
Neuroprotection market in 2016, the segment is expected to continue
its strong hold in neuroprotection market during the forecast period.
Increasing drug discovery and product launch is anticipated to drive
the Neuroprotection market growth during the forecast period.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=40553
The global Neuroprotection market on the basis of application has
been segmented to prevention and treatment. The treatment segment
held major market share in Neuroprotection market in 2016, the
segment is expected to exhibit a healthy CAGR during the forecast
period. The treatment application provides a lucrative opportunity to
manufacturers because of increasing diagnosis rate of
neurodegenerative diseases in developed economies along with higher
awareness. For instance, In the U.S. multiple sclerosis (MS) affects
approximately 400,000 individuals, and worldwide, the disease affects
2.5 million individuals, varying different geographical regions.
Well-established pharmaceutical and biotechnology industry,
increasing research activity, increasing in cadence and prevalence of
neurological disorders and growing demand for highly efficient drug
for target specific treatment of disorders is expected to increase
demand for Neuroprotection has credited for the supremacy in the
region. For instance, In December 2016, FDA approved Biogen, Inc.
drug SPINRAZA (nusinersen) to be used to treat pediatric and adult
patients suffering from spinal muscular atrophy (SMA).
North America accounted for the principal share in the global
Neuroprotection market in 2016 in terms of value, followed by Europe
and Asia Pacific. North America Neuroprotection market is expected to
expand at a healthy rate of CAGR during the forecast period from 2017
to 2025. Europe accounted for the second largest market of the
Neuroprotection. The Asia Pacific Neuroprotection market is expected
to witness a high growth rate during the forecast period. Presence of
well-established pharmaceutical and biotechnology industry,
increasing research activity, increasing in cadence and prevalence of
neurological disorders and growing demand for highly efficient drug
for target specific treatment of disorders is expected to increase
demand for Neuroprotection drugs in the region.
The report also provide profiles of leading players operating in
global neuroprotection market include Daiichi Sankyo Company, Eli
Lilly and Company, Allergan plc, Dr. Reddy’s Laboratories Ltd.,
Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc,
Astrocyte Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Biogen
Inc., and other prominent players. Increasing research, and products
launches along with along with increasing geographical footprint are
major strategies adopted by companies in neuroprotection market. For
instance, In March 2017, Dr. Reddy's Laboratories Limited entered
into a distribution agreement Integra Life Sciences Holdings
Corporation, to market and distribute Integra’s neurological
products in India.
Report Overview @
https://www.transparencymarketresearch.com/neuroprotection-market.html
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com
No comments:
Post a Comment